Initial Results from Phase II Trials of Eltrombopag or Luspatercept for Myelosuppression in Low- and Intermediate-1-Risk MDS


Initial Results from Phase II Trials of Eltrombopag or Luspatercept for Myelosuppression in Low- and Intermediate-1-Risk MDS
Slides from presentations at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/16/16)

Oliva EN et al. Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Interim results on efficacy, safety and quality of life of an international, multicenter prospective, randomized, trial. Proc ASH 2015;Abstract 91.

Giagounidis A et al. Luspatercept treatment leads to long term increases in hemoglobin and reductions in transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): Preliminary results from the Phase 2 PACE-MDS extension study. Proc ASH 2015;Abstract 92.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.